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ABSTRACT
Cysteine-rich with epidermal growth factor (EGF)-like domains 2 (CRELD2) is an endoplasmic reticulum (ER)-resident chaperone
highly activated under ER stress in conditions such as chondrodysplasias; however, its role in healthy skeletal development is
unknown. We show for the first time that cartilage-specific deletion of Creld2 results in disrupted endochondral ossification and short
limbed dwarfism, whereas deletion of Creld2 in bone results in osteopenia, with a low bone density and altered trabecular architec-
ture. Our study provides the first evidence that CRELD2 promotes the differentiation and maturation of skeletal cells by modulating
noncanonical WNT4 signaling regulated by p38 MAPK. Furthermore, we show that CRELD2 is a novel chaperone for the receptor low-
density lipoprotein receptor-related protein 1 (LRP1), promoting its transport to the cell surface, and that LRP1 directly regulates
WNT4 expression in chondrocytes through TGF-β1 signaling. Therefore, our data provide a novel link between an ER-resident chap-
erone and the essential WNT signaling pathways active during skeletal differentiation that could be applicable in other WNT-
responsive tissues. © 2020 American Society for Bone andMineral Research. © 2020 The Authors. Journal of Bone andMineral Research
published by American Society for Bone and Mineral Research..
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Introduction
The endoplasmic reticulum (ER) is the largest organelle withinthe cell and predominantly functions as the site of protein
synthesis and folding. Despite a wide range of ER-resident fold-
ing enzymes and chaperones, proteins can misfold and accumu-
late within the ER lumen, for instance due to high secretory load
or the presence of pathological mutations. This triggers an evo-
lutionarily conserved process called the unfolded protein
response (UPR).
The UPR is initiated by the ER-resident chaperone BiP dissociat-
ing from its three transmembrane receptors, protein kinase RNA-
like ER kinase (PERK), inositol-requiring enzyme 1 (IRE-1), and
activating transcription factor 6 (ATF-6), and binding to exposed
hydrophobic residues on the unfolded protein.(1) The UPR initially
acts with the aim of decreasing protein translation, increasing
refolding capacity, and degrading the misfolded protein; however,
if the stress is not returned to physiological levels, the UPR can trig-
ger cell death by inducing C/EBP homologous protein (CHOP)-
dependent/−independent signaling cascades.(2,3)
Endochondral ossification is the process responsible for the
development and postnatal growth of long bones and requires
a cartilage precursor formed by chondrocytes. The cartilage
growth plate, organized into three distinct chondrocyte differen-
tiation zones—the resting, proliferative, and hypertrophic
zones—drives long bone growth through a tightly regulated
process involving proliferation, hypertrophy, mineralization,
and apoptosis. Bone then forms on the cartilage scaffold and is
continually remodeled throughout life through the combined
actions of bone-forming osteoblasts and bone-resorbing osteo-
clasts. Interestingly, the UPR has also been implicated in the dif-
ferentiation of these highly secretory skeletal cells. For example,
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ATF4 is a transcription factor operating directly downstream of
PERK; Atf4-null mice(4) have a skeletal dysplasia phenotype due
to reduced chondrocyte differentiation and Perk-null mice(5)
exhibit osteopenia due to impaired osteoblast maturation and
activity.
The CRELD (cysteine rich with epidermal growth factor [EGF]-
like domains) family of proteins comprises CRELD1 and
CRELD2(6) and these are ER-localized(7) multidomain proteins
composed of EGF-like and calcium-binding EGF-like repeats
and a unique and highly conserved tryptophan-aspartic acid
(WE)(8) domain. During embryogenesis, CRELD1 is expressed in
various soft tissues and has been shown to play a crucial role in
heart development with CRELD1mutations associated with atrio-
ventricular septal defects.(9) CRELD2 is expressed in the develop-
ing skeleton as well as several soft tissues and to date five human
isoforms,(8) comprising varying numbers of EGF-like domains,
have been identified. In contrast, only one CRELD2 isoform,
homologous to the CRELD2α human isoform, has been identified
inmice. The precise function of CRELD2 is largely unknown; how-
ever, CRELD2β has been shown to bind to and be involved in the
folding of the nicotinic acetylcholine receptor α4 and β2 sub-
units.(10) CRELD2 was first identified as an ER stress-inducible
gene after treatment of neuro2α cells with thapsigargin(7) and
importantly, the promoter of CRELD2 contains an AFT6 response
element.(7) Unlike CRELD1, which is anchored by two C-terminal
type II transmembrane domains,(6) CRELD2 has been shown to
be secreted during ER-stress(11,12) suggesting a functional diver-
gence between the two family members. The four C-terminal
amino acids (REDL), comprising an imperfect C-terminal KDEL
ER-retention sequence, play an important role in the secretion
of CRELD2 that is further enhanced by BiP(11) and MANF(13); how-
ever, its exact role outside of the cell is currently unknown.(7)
Several studies have implicated CRELD2 in the pathobiology
of ER-stress-mediated conditions such as kidney disease(14) and
aortic aneurysm in Marfan syndrome.(15) Creld2 is also upregu-
lated and secreted in mouse models of multiple epiphyseal dys-
plasia(16) and metaphyseal chondrodysplasia type Schmid,(17)
skeletal dysplasias characterized by the retention of mutant pro-
teins in the ER of chondrocytes that results in prolonged ER
stress. Substrate-trapping experiments have shown that CRELD2
acts as a putative protein disulphide isomerase (PDI)(12) for sub-
strates such as matrilin-3, laminin 5 β3, type VI collagen, and
thrombospondin 1. Moreover, CRELD2 is upregulated in BMP9
stimulated osteogenic differentiation of mesenchymal stem cells
(MSCs) through SMAD1/6/5 binding directly to its promoter, sug-
gesting a novel role for CRELD2 in bone development.(18)
Despite these indications, the role of CRELD2 in skeletal devel-
opment and homeostasis is not clearly understood. We therefore
generated and studied in depth cartilage-specific and bone-
specific Creld2 knockout mouse models to investigate the role
of CRELD2 in skeletal development and homeostasis.
Materials and Methods
Generation of Creld2 conditional knockout mice
A Creld2 gene trap (Creld2tm1b(EUCOMM)Hmgu) targeting vector
containing a large selection cassette was obtained from the
European Conditional Mouse Mutagenesis Programme
(EUCOMM), electroporated into C57BL6 blastocysts, and used
to generate chimeras that were bred onto the C57BL6 back-
ground (Supplemental Fig. S1A). The introduction of this large
targeting vector did not abolish CRELD2 expression as identified
by Western blotting of liver tissue (Supplemental Fig. S1B).
Therefore, mice heterozygous for the targeted allele were
crossed with Actin-flp mice generating offspring with the condi-
tional Creld2 allele, which was identified by genomic DNA PCR
using the primers 50-GGT GGA CAC CTG TCA ATG GT-30 and 5’-
CAG CAT GAG AAA GGG AGC TTA-30 (Supplemental Fig. S1C).
These mice were then bred with mice expressing the Cre trans-
gene under type II collagen (Col2a1) promoter to generate Creld2
cartilage-specific knockout mice (Creld2CartΔex3–5) and under
osteocalcin (Bglap) promoter to generate bone-specific
(Creld2BoneΔex3–5) knockout mice by Cre recombination, resulting
in the deletion of exons 3–5 of Creld2. Mice with the conditional
Creld2 allele were also crossed with global deleter Cre mice, and
Western blotting of liver tissue was used to confirm that CRELD2
expression was abolished by Cre recombination (Supplemental
Fig. S1D). The presence of the Cre transgene in the conditional
lines was identified by genomic DNA PCR using the primers 5’-
TGC CAC CAG CCA GCT ATC AAC T-30 and 5’-AGC CAC CAG CTT
GCA TGA TCT C-30 (Supplemental Fig. S1E). RT-PCR was per-
formed to confirm the deletion of Creld2 in chondrocytes and
osteoblasts (Supplemental Fig. S1F). All experiments were car-
ried out in compliance with the Animals Scientific Procedures
Act 1986 according to Directive 2010/63/EU of the European Par-
liament, under project license PPL60/4525.
X-ray and micro-computed tomography (μCT)
X-ray images were obtained using the MX-20 Cabinet X-ray Sys-
tem (Faxitron, Tucson, AZ, USA). Bone measurements were taken
at 3, 6, and 9 weeks of age using the image processing program
FIJI (ImageJ).(19) To analyze bone structure, undecalcified bone
samples fixed in 4% paraformaldehyde (PFA) were subjected to
μCT analysis using the SkyScan 1174v2 (Bruker, Kontich, Bel-
gium) μCT device. Multiple 2D image projections were acquired
at 50 kV and 800 mA with a resolution of 6.74 nm. Image recon-
struction was carried out using the SkyScan NRecon program.
Common standard 3D bone morphometric parameters were
determined for trabecular and cortical bone using the CTAn pro-
gram.(20) Trabecular bone architecture was calculated from
350 serial slides of 6 microns thick, 650 μm from the growth
plate. Cortical bone architecture was calculated from 100 serial
slides of 6 microns thick, 3.5 mm from the growth plate.
Histological and immunohistochemical staining of cartilage
Cartilage samples were fixed for histology and immunohisto-
chemistry and processed as outlined previously.(21) Formalin-
fixed sections were stained with hematoxylin and eosin (H&E)
and toluidine blue. For immunohistochemistry (IHC), antigen
retrieval was performed by incubation in 0.2% bovine hyaluron-
idase, 0.2% Triton-X, and 20 μg/mL proteinase K. Sections were
blocked in serum for 1 hour, incubated in primary antibody over-
night at 4 C, and probed with the appropriate secondary anti-
body for 1 hour at room temperature. Sections were mounted
in Fluoroshield mounting media with DAPI (Abcam, Cambridge,
UK). The following primary antibodies were used: acetylated-
tubulin (ab24610), collagen I (ab34710), collagen II (ab34712)
(all from Abcam), CRELD2 (sc86110, Santa Cruz Biotechnology,
Dallas, TX, USA), matrilin-3 (AF3357, R&D Systems, Minneapolis,
MN, USA), aggrecan (Professor Tim Hardingham, The University
of Manchester), and collagen X (Professor Karl Kadler, The Uni-
versity of Manchester). Negative controls are shown in Supple-
mental Fig. S2F. To analyze chondrocyte proliferation, 3-week-
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old mice were injected subcutaneously with BrdU labeling
reagent according to weight (0.1 mg per 10 g). Two hours after
injection, mice were euthanized and limbs harvested. IHC was
then performed to detect BrdU-positive cells using an anti-BrdU
antibody (ab6326, Abcam). BrdU-positive cells in the proliferative
zone of the growth plate were counted using the watershed
algorithm in the FIJI program and expressed as a percentage of
the total number of osteoblasts or the total number of chondro-
cytes within the proliferative zone. Analysis was performed on
three matched slides per mouse from three mice per genotype.
TUNEL analysis
Cell death was detected by fragmented DNA and quantified
using the DeadEND Fluorometric TUNEL System (Promega, Mad-
ison, WI, USA) according to manufacturer’s instructions. Permea-
bilization was performed by boiling samples in citric buffer pH 6
as Proteinase K treatment can generate false positives.(22)
TUNEL-positive cells were counted using the watershed algo-
rithm in FIJI and were expressed as a percentage of the total
number of osteoblasts or the total number of chondrocytes
within each zone of the growth plate. Analysis was performed
on three matched slides per mouse from three mice per
genotype.
Transmission electron microscopy (TEM)
Tibial cartilage from 1-week-old pups was dissected and fixed in
2% glutaraldehyde in 0.1 M sodium cacodylate buffer at 4C.
Samples were then processed, embedded, and sectioned by
the Electron Microscopy Research Services Unit at Newcastle
University. The protocol was as follows. Cartilage samples were
then washed three times in 0.1 M sodium cacodylate and fixed
a second time in 2% (w/v) osmium tetroxide in distilled water.
Tissues were then rinsed twice in water, immersed in 2% uranyl
acetate, and rinsed twice again in water before being washed
with 25%, 50%, 75% acetone. Samples were then incubated in
two changes of 100% acetone and embedded using the TAAB
epoxy resin kit according to manufacturer’s specification. To
allow for resin to fully penetrate the tissues, samples were incu-
bated in 100% resin for 2 days. Tibial cartilage samples were then
placed in a mold and resin was polymerized overnight at 60C.
After embedding, samples were sectioned to ultrathin sections
of 70 nm using a diamond knife on a Leica (Buffalo Grove, IL,
USA) EM UC7 ultramicrotome, stretched with chloroform and
mounted onto Pioloform-filmed copper grids. Prepared grids
were then stained with 2% aqueous uranyl acetate and lead cit-
rate solution. Prepared grids were imaged using the Phillips
CM100 Transmission Electron Microscope.
Bone histomorphometry
Nine-week-old tibias were dissected and fixed in 4% formalde-
hyde for 24 hours and embedded in methylmethacrylate with-
out decalcification. Sections (6 μm) were stained with Von
Kossa (to analyze calcification), 1% toluidine blue (to analyze
osteoblast number(23)), and stained for TRAcP (to analyze osteo-
clast number and surface(23)). To study the dynamic parameters
of bone, mice were injected in the intraperitoneal cavity 1 week
and 1 day before euthanization with 30 mg/kg alizarin complex-
one and 20 mg/kg calcein in a 2% sodium bicarbonate pH 7.4
solution, respectively. Trabecular bone histomorphometric mea-
surements were performed on 6-μm-thick sections from fluores-
cent images acquired using a Zeiss (Thornwood, NY, USA) Axio
imager 2 microscope. The analysis of the bone formation rate
(BFR)(23) was carried out on matched sections from 5 mice per
genotype and was performed on the trabecular bone in the
proximal tibia, 100 μm below the growth plate.
Primary cell extraction and cell culture
MSCs were isolated from bone marrow aspirates, cultured and
phenotyped as previously described.(24,25) Primary chondrocytes
were isolated after digestion of 5-day-old costal and tibial carti-
lage with 2.5 mg/mL collagenase IA as outlined previously.(21)
Primary chondrocytes were cultured for up to 7 days in complete
DMEM/F-12 (supplemented with 10% FBS, 5% non-essential
amino acids, 1 U/mL penicillin, 1 μg/mL streptomycin, and
50 μg/mL L-ascorbate-2-phosphate). Primary osteoblasts were
isolated from 1-week-old neonatal calvarias by sequential enzy-
matic digestion of the bone matrix.(26) Cells released in the sec-
ond and third digestion were pelleted by centrifugation and
cultured in complete alpha MEM (supplemented with 10% FBS,
1 U/mL penicillin, and 1 μg/mL streptomycin). To generate
mature osteoblasts, primary osteoblasts were cultured for
21 days in osteogenic media (complete alpha MEM containing
50 μg/mL L-ascorbate-2-phosphate, 10 mM β-glyceropho-
sphate, and 0.1 μM dexamethasone). Osteoclast precursors were
isolated from the long bones of 6- to 9-day-old mice.(27) The
bone marrow mononuclear cell fraction was obtained by centri-
fugation of Histopaque-1077. Cells were plated in 12-well plates
and cultured for 48 hours in complete alpha MEM containing
30 ng/mL M-CSF (R&D Systems) generating M-CSF-dependent
macrophages. Osteoclastogenesis was performed by culturing
macrophages for 1 week in complete alpha MEM supplemented
with 30 ng/mL M-CSF and 100 ng/mL RANKL (R&D Systems).
Osteoclastogenesis media was refreshed every 2 days. To ana-
lyze the effect of wild-type and Creld2 knockout primary osteo-
blast conditioned media, osteoclastogenesis was performed in
conditioned media. The SW1353 chondrocyte-like and the
SAOS2 osteoblast-like cell lines were maintained in complete
DMEM/F-12 and complete alpha MEM, respectively. For WNT4
stimulation studies, recombinant WNT4 (R&D Systems) was
added at a concentration of 100 ng/mL. For TGFβ1 stimulation
studies, recombinant TGFβ1 (R&D Systems) was added at a con-
centration of 5 ng/mL.
Protein extraction and immunoblotting
Protein lysates were extracted as outlined previously.(21) Protein
concentrations were obtained using the Pierce (Rockford, IL,
USA) BCA kit. Samples were denatured by boiling and reduced
by DTT where appropriate. For analysis of plasma membrane
protein expression, plasma membranes were extracted using
the plasma membrane protein extraction kit from Abcam. West-
ern blotting was performed as outlined previously.(21) The fol-
lowing primary antibodies were used: p38 (ab170099),
Phospho p38 (T180 + Y182) (ab195049), β-catenin (ab32572),
osteoprotegerin (ab183910), LRP1 β-chain (ab92544), alpha
1 sodium potassium ATPase antibody (ab7671) (all from Abcam),
GAPDH (Millipore, Burlington, MA, USA), and CRELD2 and RANKL
(sc377079, Santa Cruz). Membranes were imaged on the LI-COR
Odyssey CLx Imaging System. Densitometric analysis of the fluo-
rescent protein bands was presented relative to protein loading
or GAPDH levels. Analysis was performed on three samples per
condition.
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Enzyme-linked immunosorbent assay (ELISA)
To determine the concentration of secreted RANKL and OPG in
osteoblast conditioned media, media was concentrated using
the Vivaspin 15 MWCO centrifugal concentrators for 30 minutes
at 15,000g. The mouse RANKL and mouse Osteoprotegerin
Quantikine ELISA kits from R&D systems were then used to deter-
mine protein concentration in the concentrated conditioned
media as outlined in the manufacturer’s instructions.
RNA extraction and sequencing
RNA was extracted from whole knee joint cartilage of 5-day-old
mice using the Promega Reliaprep RNA Tissue Miniprep System
as outlined previously.(21) RNA was also extracted from cells
using the Promega Reliaprep RNA Cell Miniprep System accord-
ing to the manufacturer’s protocol. The extracted RNA from car-
tilage knee joints and primary osteoblasts were sent to GATC
Biotech for RNAseq analysis. Each of the three samples contained
two individually extracted RNA samples, pooled into one sample
at a concentration of 1 μg RNA with a RIN >8. The RNA was
sequenced and analyzed by GATC Biotech. Briefly, Bowtie was
used to align the RNA sequencing reads to the mouse reference
genome. TopHat, Cufflinks, and Cuffmerge were used to identify
exon-exon splice junctions, and identify, quantify, and annotate
the processed RNA-sequencing alignment assembly. Cuffdiff
was then used to determine differential expression levels of
wild-type and knockout merged transcripts. Several RNA-
sequencing hits were confirmed by quantitative-PCR (qPCR).
Quantitative-PCR (qPCR)
cDNA was synthesized from RNA using the GoScript Reverse
Transcription System according to the manufacturer’s protocol.
RNA was removed after the incubation with 1 U RNase H for
20 minutes at 37C. qPCR was performed using the Power SYBR
Green method as outlined in the manufacturer’s instructions on
a Bio-Rad (Hercules, CA, USA) DNA engine Peltier Thermal Cycler.
For primer sequences, see Supplemental Table S7. Samples were
analyzed in duplicate on each plate and the level of cDNA was
normalized to the level of 18S. qPCR results presented in Fig. 4
were obtained by TaqMan real-time PCR as described previ-
ously.(25) Sequences for TaqMan qPCR primers and correspond-
ing Universal Probe Library (UPL) probes are outlined in
Supplemental Table S8.
siRNA gene silencing
For siRNA transfection, 100 nM SMARTpool ON-TARGETplus
siRNA of four specific siRNA duplexes were used to target CRELD2
(L-010856, Horizon, Dharmacon, Lafayette, CO, USA) and LRP1 (L-
004721, Horizon, Dharmacon). This was transfected into cells
using the Dharmafect transfection reagent 1 (Horizon, Dharma-
con). Reduction of gene-specific mRNA levels was calculated by
comparing levels on cells transfected with 100 nM siCONTROL
non-targetting siRNA (D-001206-14). For chondrogenesis, MSCs
were transfected once before the induction of chondrogenesis.
For osteogenesis experiments, MSCs in monolayer were trans-
fected every week with siRNA for the duration of the experiment.
MSC differentiation and validation
For chondrogenesis, MSCs were cultured as a pellet in chondro-
genic medium (DMEM supplemented with 1 U/mL penicillin,
1 μg/mL streptomycin, 100 μg/mL sodium pyruvate, 100 nM
dexamethasone, 50 μg/mL L-ascorbate-2-phosphate, 1X ITS-1
premix, 10 ng/mL TGFβ3). For histology, either 500,000 (large)
or 100,000 (mini) MSCs were seeded into a pellet. For gene
expression analysis, 150,000 MSCs were seeded into a pellet.
Chondrogenic media was replaced every 2 to 3 days for 14 days.
For osteogenesis, MSCs were seeded in monolayer and induced
to differentiate in osteogenic media as outlined above. Osteo-
genic media was replaced every 2 to 3 days for 21 days. For
WNT4 recovery studies, recombinant WNT4 (R&D Systems) was
added at a concentration of 100 ng/mL and was added to the
culture from day 4 (chondrogenesis) and day 7 (osteogenesis).
Analysis of osteoblast differentiation and activity in vitro
Alizarin Red S stainingwas performed onmature osteoblastmono-
layers to analyze mineralization. Briefly, monolayers were fixed in
4% PFA and stained with 40 mM Alizarin Red S for 30 minutes.
Staining intensity was calculated relative to Alizarin Red S stan-
dards at a wavelength of 405 nm. Alkaline phosphatase activity
was determined on mature osteoblast protein lysates using the
alkaline phosphatase colorimetric assay kit from Abcam. Analysis
was performed on three samples per condition.
Co-immunoprecipitation and mass spectrometry
A previously generated V5-tagged wild-type CRELD2 cDNA con-
struct in pcDNA 3.1 (+)(12) was used to overexpress CRELD2 in the
chondrocyte-like SW1353 and osteoblast-like SAOS2 cell lines. To
assess the binding partners of CRELD2, protein–protein interac-
tions were cross-linked by incubation in 1.0 mM DSP for
10 minutes at room temperature. The reaction was stopped
upon the addition of Tris-HCl pH 7.5 added to a final concentra-
tion of 20 mM for 15 minutes at room temperature. Cellular pro-
teins were harvested and clarified by centrifugation at 10,000g.
Lysates were precleared with 5% (v/v) protein A Sepharose for
30 minutes at 4C with gentle rotation. Protein lysate (500 μg)
was added to the anti-V5 agarose beads and incubated over-
night at 4C under gentle rotation. CRELD2 interacting proteins
were identified by LC/MS-MS performed by the Mass Spectrom-
etry Facility at The University of Manchester.
Immunocytochemistry
To assess the intracellular localization of CRELD2, primary chondro-
cytes were fixed in 10% formalin for 10 minutes at room tempera-
ture. Plasmamembranes were labeledwith wheat germ agglutinin
(WGA) AlexaFluor 594 conjugate. Cells were then permeabilized for
5 minutes in 0.5% Triton-X before immunolabeling. The following
primary antibodies were used: CRELD2, GRP94 (sc1794, Santa
Cruz), GLG1 (AF7879, Biotechne), and EEA1 (AF8047, R&D Systems).
For labeling of membrane LRP1, living cells were incubated for
2 hours at 37C in a primary antibody raised against LRP-1 clone
8G1 that detects the extracellular LRP1 α-chain (Abcam). The cells
were washed three times in PBS and incubated in an anti-mouse
secondary antibody labeled with AlexaFluor 488 for 20 minutes
at 13C. Cells were then fixed in 10% formalin for 10 minutes at
room temperature. Immunocytochemistry slides were mounted
in Fluoroshield mounting media with DAPI and images were
acquired at ×630 magnification using a Nikon (Tokyo, Japan) A1R
confocal microscope.
Statistics
Results are expressed as the mean  the standard deviation
(SD) of a minimum of three individual experiments/mice.
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Statistical significance was analyzed by Student’s unpaired t test,
and statistical significance was p < 0.05.
Results
The ablation of Creld2 impairs skeletal development
To study the role of CRELD2 specifically in cartilage and bone
development, we generated Creld2 conditional knockout mouse
models (Supplemental Fig. S1).
Interestingly, cartilage-specific Creld2 knockout mice (Creld2-
CartΔEx3–5) displayed a chondrodysplasia-like phenotype with dis-
proportionate short stature due to impaired endochondral
ossification (Fig. 1A). For example, the long bones of Creld2-
CartΔEx3–5 mice were significantly shorter than controls and they
also displayed reduced bone density with disrupted trabecular
bone architecture (Fig. 1B). In contrast, intramembranous ossifi-
cation of the cranial bones, measured by the inner canthal dis-
tance (ICD), was unaffected. Hematoxylin and eosin (H&E)
staining of cartilage growth plate sections from 3-week-old
Creld2CartΔEx3–5 mice revealed a disrupted growth plate with
numerous areas of hypocellularity and an overall reduction in
the number of chondrocytes within individual growth plate
zones (Fig. 1C).
Disruptions to primary cilia length and orientation result in
growth plate defects and lead to cell misalignment(28) and
abnormal cell morphology. It has been suggested that the
columnar organization of chondrocytes within the proliferative
zone may be controlled by primary cilia that normally align in
an axis parallel to bone growth.(29) Interestingly, the proliferative
zone of Creld2CartΔEx3–5 growth plates lacked the typical colum-
nar organization observed in controls, and primary cilia in the
mutant mice were no longer aligned in an axis parallel to bone
growth(29) (Fig. 1C and Supplemental Fig. S2B). In the hypertro-
phic zone, matrix mineralization creates a hypoxic environment
depleted of nutrients and results in chondrocyte death. Whereas
the late hypertrophic zone of growth plates in control mice were
characterized by cellular debris, in Creld2CartΔEx3–5 mice, chondro-
cytes were present within the newly ossified bone (Fig. 1C) and
displayed an abnormal morphology that was more indicative
of elliptical-looking proliferative chondrocytes (Supplemental
Fig. S2A). Additionally, the height of the zone of type X collagen
expression (a marker of chondrocyte hypertrophy) was signifi-
cantly reduced in the Creld2-null growth plates, suggesting a
decrease in numbers of mature hypertrophic chondrocytes
(Fig. 1D). In contrast, the expression of other cartilage extracellu-
lar matrix proteins was unaffected (Supplemental Fig. S2C). Con-
sistent with changes observed in other mouse models of human
growth plate dysplasias,(16,30,31) moreover, the deletion of Creld2
in chondrocytes significantly reduced cell proliferation and
increased apoptosis (Fig. 1E). Thus, we conclude that Creld2 abla-
tion in chondrocytes impairs endochondral ossification by dis-
rupting chondrocyte maturation and survival within the growth
plate.
The ablation of Creld2 impairs bone homeostasis
Interestingly, the bone-specific Creld2 knockout mice
(Creld2BoneΔEx3–5) demonstrated growth retardation (Fig. 2A)
and showed an osteopenic phenotype characterized by signifi-
cantly reduced bone mass with altered trabecular and cortical
architecture (Fig. 2B). Toluidine blue staining revealed signifi-
cantly less mature bone-forming osteoblasts and osteocytes in
Creld2BoneΔEx3–5 mice compared with controls (Fig. 2C). Further-
more, deletion of Creld2 in mature osteoblasts resulted in
increased osteoblast apoptosis in vitro (Fig. 2D) and a reduction
in the rate of bone formation as demonstrated by dynamic histo-
morphometry (Fig. 2E). In addition, there was also a significant
increase in the osteoclast number and the erosion surface in
Creld2BoneΔEx3–5 bones as identified by staining for the osteoclast
marker tartrate-resistant acid phosphatase (TRAcP)
(Supplemental Fig. S3A).
The cross-talk between osteoblasts and osteoclasts is central
to maintaining bone homeostasis. Therefore, we next measured
the expression of the osteoclastogenic cytokine receptor activa-
tor of nuclear factor kappa-Β ligand (RANKL) and its decoy recep-
tor osteoprotegerin (OPG) that inhibits osteoclastogenesis. The
RANKL/OPG axis was disrupted at both the RNA and protein level
in osteoblasts from Creld2BoneΔEx3–5 mice. RANKL expression at
both the gene (Tnfsf11) and protein level was upregulated in
Creld2BoneΔEx3–5 osteoblasts; however, OPG expression at the
gene (Tnfrsf11b) and protein level was unchanged
(Supplemental Fig. S3B). Additionally, the levels of secreted
RANKL were significantly increased in media collected from
Creld2BoneΔEx3–5 osteoblasts in vitro, whereas the secretion of
OPG was increased (Supplemental Fig. S3C). Overall these data
suggested that the upregulation of RANKL expression could
result in the significant increase in osteoclast number in
Creld2BoneΔEx3–5 mice. To verify whether the impaired RANKL/
OPG ratio in Creld2BoneΔEx3–5 osteoblasts stimulated osteoclasto-
genesis, we differentiated pre-osteoclasts in vitro in conditioned
media from the osteoblasts of Creld2BoneΔEx3–5 and control mice.
The levels of several osteoclast markers (Acp5, Calcr, and Ctsk)
were significantly upregulated in primary osteoclasts differenti-
ated in Creld2BoneΔEx3–5 conditioned media, indicating that dis-
rupted RANKL/OPG axis promotes osteoclast formation
(Supplemental Fig. S3D). Thus, we conclude that CRELD2 defi-
ciency in mature osteoblasts impairs bone homeostasis by
impairing osteoblast maturation, activity, and survival and by
disrupting osteoblast/osteoclast cross-talk.
The deletion of Creld2 disrupts WNT signaling
To further assess the effect of CRELD2 deletion on chondrogen-
esis and osteogenesis, we analyzed the global gene expression
profiles of both Creld2 knockout chondrocytes and mature oste-
oblasts by RNA-sequencing. After the ablation of Creld2,
220 genes were differentially expressed in chondrocytes (Fig.
3A) compared with 1021 in osteoblasts (Fig. 3B). The enriched
Gene Ontology (GO) term clusters for the differentially expressed
genes in Creld2CartΔEx3–5 chondrocytes (Supplemental Table
Table S1) and Creld2BoneΔEx3–5 mature osteoblasts
(Supplemental Table S2) comprised genes with ubiquitous cellu-
lar function and genes related to skeletal development and ossi-
fication. Of particular note, genes involved in cell cycle arrest,
apoptosis, and embryonic skeletal system development were
differentially expressed in Creld2CartΔEx3–5 chondrocytes. The
expression of several key genes was verified by qPCR (Fig. 3C).
For example, Mmp13 encoding a matrix metalloproteinase and
a marker of chondrocyte hypertrophy(32) was significantly down-
regulated in Creld2CartΔEx3–5 chondrocytes. Additionally, the
expression of Cyr61, encoding Cysteine-rich protein 61 that pro-
motes chondrogenesis in vitro,(33) was also downregulated in
Creld2CartΔEx3–5 mice. Similar to the GO clusters from
Creld2CartΔEx3–5 chondrocytes, differentially expressed genes in
Creld2BoneΔEx3–5 mature osteoblasts clustered into genes
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Fig. 1. Creld2CartΔEx3–5 display a chondrodysplasia phenotype with a disrupted epiphyseal growth plate due to impaired chondrocyte maturation and survival. (A)
Representative X-ray images at age 9 weeks and bonemeasurements showing a defect in endochondral ossification. Scale bar = 5 mm. (n= >10per genotype.) (B)
Bonemicroarchitecture analysis at age 9 weeks from μCT (representative images of sagittal and transverse projection). Scale bar = 500 μm. n = >10 per genotype.
(C) Hematoxylin and eosin (H&E) staining and quantification of growth plate parameters at age 3 weeks. Misaligned chondrocytes highlighted in box 1 (magnified
in box 3). Retained chondrocytes at the chondro-osseous boundary highlighted in box 2 (magnified in box 4). Areas of hypocellularity indicated by and asterisk. RZ
= resting zone; PZ=proliferative zone; HZ=hypertrophic zone. Scale bar =100μm.n= 3per genotype. (D) IHC staining for thehypertrophicmarker typeX collagen
at age 3 weeks (collagenX: red; nuclei counterstainedwithDAPI: blue) andmeasurement of zone of staining. Scale bar = 100μm.n= 3per genotype. (E) TUNEL and
analysis of IHC staining for BrdU at age 3 weeks. BV/TV = bone volume/total volume; Tb.N = trabecular number; RZ = resting zone; PZ = proliferative zone; HZ =
hypertrophic zone. n = 3 per genotype. All graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
Fig. 2. Creld2BoneΔEx3–5displayanosteopenicphenotypeduetoimpairedosteoblastactivity. (A)RepresentativeX-rayimagesatage9 weeksandbonemeasurements.
Scale bar = 5 mm. n= >10 per genotype. (B) Bonemicroarchitecture analysis at age 9 weeks from μCT (representative images of sagittal and transverse projection).
Scale bar = 500 μm. n = >10 per genotype. (C) Toluidine blue staining and quantification of osteoblast (cuboidal osteoblasts lining the bone indicated with red
arrow)/osteocyte (indicatedwithblack arrow)numbers at age9 weeks. Scalebar=100μm.n= 5pergenotype. (D) TUNELanalysis of apoptosis of osteoblasts invitro
(n= 3pergenotype). (E)Fluorochromelabelingofboneandanalysisofdynamicboneparameters.BFR=boneformationrate.Scalebar=25μm.n= 8pergenotype. (E)
TUNEL and analysis of immunohistochemical staining of BrdU (n = 3 per genotype). BV/TV = bone volume/total volume; Tb.N = trabecular number; Ct.Po = cortical
porosity; Ob.N/BS = osteoblast number/bone surface; Ot.N/BA= osteocyte number/bone area. All graphs are displayed asmean  SD, *p< 0.05, **p< 0.005.
Fig. 3. RNA-sequencing indicates that the lack of Creld2 disrupts WNT signaling in chondrocytes and osteoblasts and impairs osteogenic and chondrogenic
differentiation. Volcano plots of differential gene expression in Creld2CartΔEx3–5 chondrocytes (A) and Creld2BoneΔEx3–5 mature osteoblasts (B). Differentially
expressed genes with statistical significance (false discovery rate [FDR] adjusted p value <0.05) are indicatedwith a red dot (fold change >1.5-fold) and nonsig-
nificantgenes are indicatedwith a black dot. (C) qRT-PCRanalysis ofCyr61 andMmp13 inCreld2CartΔEx3–5 and control chondrocytes. (D) qRT-PCRanalysis of Spp1,
Bglap, and Sost in Creld2BoneΔEx3–5 and control mature osteoblasts. (E) Venn diagram of differential genes (FDR adjusted p value <0.05) between Creld2CartΔex3–5
chondrocytes andCreld2BoneΔex3–5mature osteoblasts. Table ofGO terms for the23differentially expressedgenes in commonbetweenCreld2CartΔex3–5 chondro-
cytes and Creld2BoneΔex3–5mature osteoblasts (FDR adjusted p value <0.05). (F) qRT-PCR analysis ofWnt4 expression in Creld2CartΔEx3–5 and control chondrocytes
and Creld2BoneΔex3–5 and control mature osteoblasts. n = 3 per genotype. Graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
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Fig. 4. CRELD2 plays a role in chondrogenic and osteogenic differentiation of hMSCs. (A) Western blot showing successful knockdown of CRELD2 expression
using gene silencing siRNA. Equal loading shown by GAPDH. (B) Weights of control (siCON) and CRELD2 knockdown (siCRELD2) chondrocyte pellets. Scale
bar = 5 mm. (C) Histology staining of chondrocyte pellets (H&E, toluidine blue staining) showing proteoglycans and immunohistochemistry for collagen II
expression (collagen II: red; nuclei counterstainedwith DAPI: blue). Scale bar = 200 μm. (D) qRT-PCR analysis of CRELD2 and chondrocytemarker genes in siCON
and siCRELD2 chondrocytes. (E) Alizarin red staining of matrix mineralization in themonolayer culture of hMSC-derived osteoblasts and optical density quanti-
ficationof staining intensity.n= 3pergenotype. (F)Quantificationof alkalinephosphatase (ALP) activity in siCONandsiCRELD2osteoblasts. (G) qRT-PCRanalysis
of CRELD2 and osteoblast marker genes in siCON and siCRELD2 osteoblasts. n = 3 per genotype. Graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
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involved in the cell cycle, apoptosis, and ossification. qPCR was
used to verify the expression of four key genes differentially
expressed in Creld2 knockout osteoblasts (Fig. 3D). The expres-
sion of the immature osteoblast marker Spp1 was upregulated,
whereas Bglap and Sost, both markers of mature osteoblasts
and osteocytes, were downregulated. Overall these data further
confirm that the deletion of Creld2 in chondrocytes and mature
osteoblasts results in impaired differentiation and maturation.
Twenty-three genes (17 upregulated, 6 downregulated) were
differentially expressed in common between Creld2CartΔEx3–5
chondrocytes and Creld2BoneΔEx3–5 mature osteoblasts
(Supplemental Table S3). These clustered into genes involved
in extracellular matrix organization, biomineral tissue develop-
ment, and negative regulation of fibroblast growth factor signal-
ing (Fig. 3E). Interestingly Wnt4, encoding a secreted signaling
protein that can modulate chondrocyte maturation(34) and
enhance osteogenic differentiation,(35) was downregulated in
both Creld2CartΔEx3–5 chondrocytes and Creld2BoneΔEx3–5 mature
osteoblasts (Fig. 3F), which could explain the delay in chondro-
cyte and osteoblast maturation observed in both the
Creld2CartΔEx3–5 and Creld2BoneΔEx3–5 mice, respectively.
CRELD2 modulates WNT signaling during chondrogenic
and osteogenic differentiation
We further examined the role of CRELD2 in chondrocyte and oste-
oblast differentiation by silencing CRELD2 expression using siRNA
during in vitro chondrogenic and osteogenic differentiation of
human mesenchymal stem cells (hMSCs). Successful knockdown
of CRELD2 was confirmed by Western blotting before MSC differ-
entiation (Fig. 4A). CRELD2 knockdown (siCRELD2) resulted in smal-
ler cartilage pellets compared with control (siCON) pellets,
indicating that CRELD2 plays a prominent role in regulating early
chondrogenesis (Fig. 4B, C). siCRELD2 pellets showed a disrupted
ECM composition characterized by a reduction in toluidine blue
(proteoglycan stain) and type II collagen staining (Fig. 4C). Addi-
tionally, expression levels of several chondrogenic markers (SOX9,
IHH, COL2A1, ACAN, and COL10A1) were significantly reduced in
siCRELD2 chondrocytes, indicating chondrocyte differentiation
was impaired after the knockdown of CRELD2 (Fig. 4D).
Osteogenic differentiation of siCRELD2 hMSCs was also dis-
rupted, as characterized by a significant reduction in matrix miner-
alization (Fig. 4E) and alkaline phosphatase (ALP) activity (Fig. 4F).
Several well-established osteoblast marker genes were differen-
tially expressed after the knockdown of CRELD2 (Fig. 4G). For exam-
ple, COL1A1 and ALPL involved in bone matrix formation and
mineralization; SPP1, BGLAP, and SOST, markers of immature and
mature osteoblasts and osteocytes, respectively, were significantly
reduced in siCRELD2 osteoblasts, indicating the knockdown of
CRELD2 impaired osteoblast differentiation and osteogenesis.
It was of particular significance that both siCRELD2 hMSC-
derived chondrocytes and osteoblasts exhibited a significant
reduction in WNT4 expression (Fig. 4D, G), consistent with its
reduced expression levels in primary chondrocytes andosteoblasts
from the Creld2 knockout mice (Fig. 3). These data suggest that
CRELD2 plays an important role in hMSC chondrogenic and osteo-
genic differentiation potentially via modulatingWNT4 signaling.
CRELD2 promotes the membrane expression of LRP1
Immunocytochemistry was used to analyze the subcellular local-
ization of CRELD2 in primary chondrocytes. CRELD2 co-localized
with the ER marker heat shock protein 90 kDa beta member
1 (also known as GRP94), the Golgi marker Golgi apparatus pro-
tein 1 (GLG1), and the exosomal marker Cluster of differentiation
81 (CD81), thereby suggesting a potential role for this chaperone
in trafficking proteins from the ER through the secretory path-
way (Supplemental Fig. S4).
To further elucidate the role of CRELD2 in chondrocyte and
osteoblast biology, putative CRELD2 binding partners were iden-
tified by co-immunoprecipitation (Co-IP) performed using
recombinant V5-tagged CRELD2 overexpressed in the SW1353
(chondrocyte-like) and the SAOS2 (osteoblast-like) cell lines as
previously described.(12) Co-IP proteins were identified by LC–
MS/MS performed on Co-IP protein pools and 66 potential
CRELD2 binding partners in SW1353 cells (top 50 shown in Sup-
plemental Table S4) and 99 potential CRELD2 binding partners in
SAOS2 cells (top 50 shown in Supplemental Table S5) were iden-
tified. Interestingly, there were only 28 binding partners in com-
mon between SW1353 and SAOS2 cells (Supplemental Table S6).
In both cell types, CRELD2 was found to bind to DNAJ proteins,
peptidyl prolyl-isomerases (PPIs) and PDIs that function as chap-
erones involved in the folding and processing of nascent pro-
teins, further confirming its ER localization. CRELD2 also bound
to protein complexes involved in the processing of collagen
fibrils, such as collagen prolyl-hydroxylases as well as several col-
lagen alpha chains including collagen alpha-2(1) suggesting a
putative role for CRELD2 in collagen folding; however, there
was no evidence of collagen retention in knockout cells. Further-
more, CRELD2 was also found to bind the receptor low-density
lipoprotein receptor-related protein 1 (LRP1) and the mesoderm
development LRP chaperone (MESD) in both cell lines, indicating
that it may function as a chaperone in assisting the folding, mat-
uration, and transport of LRP1 through the secretory pathway
during skeletal development.
To study the role of CRELD2 in LRP1 membrane trafficking,
CRELD2 expression was knocked down in SW1353 and SAOS2
cells using siRNA. Successful knockdown was confirmed by qPCR
and Western blotting (Fig. 5A, B). It is important to note that the
expression of LRP1 was not changed at either the RNA or protein
level after the ablation of CRELD2 in siRNA-treated SW1353 and
SAOS2 cells (Fig. 5A, B). However, live immunolabeling (Fig. 5C)
and Western blotting (Fig. 5D) of the membrane fraction
revealed that there was significantly less staining of LRP1 at the
membrane in both SW1353 and SAOS2 knockdown cells. Thus,
in chondrocytes and osteoblasts, CRELD2 potentially functions
as a novel LRP1 chaperone through the secretory pathway and
promotes LRP1 expression at the cell surface.
WNT4 expression is driven by LRP1 in chondrocytes but
not in osteoblasts
To determine whether reduced LRP1 membrane expression
results in impaired chondrocyte and osteoblast maturation,
LRP1 expression was silenced during in vitro chondrogenic and
osteogenic differentiation of hMSCs using siRNA. Successful
knockdown of LRP1 was confirmed by Western blotting (Fig. 6A).
The knockdown of LRP1 during chondrogenesis resulted in
significantly smaller siLRP1 cartilage pellets (Fig. 6B, C); however,
this difference in size was not as pronounced as observed with
siCRELD2 cartilage pellets. siLRP1 pellets displayed reduced
matrix staining for type II collagen; however, unlike the altered
proteoglycan composition observed in siCRELD2 pellets, matrix
staining (Fig. 6C) and gene expression levels (Fig. 6D) for the
major cartilage proteoglycan aggrecan were comparable
between control and siLRP1 pellets, suggesting that CRELD2
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Fig. 5. CRELD2promotes themembraneexpressionofLRP1. (A) qRT-PCRanalysisofCRELD2andLRP1 in siCONandsiCRELD2SW1353chondrocyte-likeandSAOS2
osteoblast-like cells. (B) Western blot showing successful knockdown of CRELD2 expression using gene silencing siRNA in SW1353 and SAOS2 cells. The levels of
LRP1 in control and knockdown cells were determined byWestern blot band densitometry. Equal loading shown by GAPDH. (C) Representative images of live cell
surface LRP1 labelling and quantification of immunocytochemical staining of membrane LRP1 in control and knockdown cells. (D) Western blot showing LRP1
expression in the membrane fraction from control and knockdown cells. These levels were quantified by band densitometry. Equal loading shown by Alpha-1
sodium potassium ATPase (plasmamembrane marker). Scale bar = 10 μm. n = 3 per genotype. Graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
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Fig. 6. LRP1 promotes WNT4 expression during chondrogenic differentiation of MSCs but not during osteogenesis. (A) Western blot showing successful
knockdown of LRP1 expression using gene silencing siRNA. Equal loading shown by GAPDH. (B) Representative images and quantification of the average area
of control (siCON) and LRP1 knockdown (siLRP1) chondrocytemini pellets comparedwith the averagearea of CRELD2 knockdown (siCRELD2)mini pellets. Scale
bar = 100 μm. (C) Histology staining of chondrocyte pellets (H&E and immunohistochemistry for collagen II and Aggrecan expression). Scale bar = 100 μm. (D)
qRT-PCR analysis of LRP1 and chondrocyte marker genes in siCON and siLRP1 chondrocytes. (E) Alizarin red staining of matrix monolayer of MSC-derived oste-
oblasts and quantification of staining intensity. (F) Quantification of ALP activity in siCON and siLRP1 osteoblasts. (G) qRT-PCR analysis of LRP1 and osteoblast
marker genes in siCON and siLRP1 osteoblasts. n = 3 per genotype. Graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
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Fig. 7. The lack of CRELD2 in chondrocytes and osteoblasts disrupts p38MAPK signaling. (A) qRT-PCR analysis of CRELD2, LRP1, andWNT4 in control (siCON) and
CRELD2 (siCRELD2) and LRP1 (siLRP1) knockdown SW1353 cells. (B) Western blot showing β-catenin, p38, and phospho p38 (pp38) expression in siCON and
siCRELD2 SW1353 chondrocyte-like cells. Levels were determined by Western blot densitometry. (C) Western blot showing p38 and pp38 expression in siCON
and siCRELD2 SW1353 cells after treatment with recombinant WTN4 (rWNT4). (D) qRT-PCR analysis ofWNT4 expression in control and siLRP1 SW1353 cells after
treatment with recombinant TGF-β1 (rTGF-β1). (E) qRT-PCR analysis of CRELD2, LRP1, andWNT4 in control and knockdown SAOS2 cells. (F) Western blot showing
β-catenin, p38, and pp38 expression in siCON and siCRELD2 SAOS2 osteoblast-like cells. Levels were determined by Western blot densitometry. (G) Western blot
showingp38andpp38 expression in siCONand siCRELD2 SAOS2 cells after treatmentwith rWNT4. Equal loading shownbyGAPDH.n= 3per genotype. All graphs
are displayed as mean  SD, *p < 0.05, **p < 0.005.
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may play additional roles during chondrogenesis besides
chaperoning LRP1. The expression levels of several chondro-
genic markers (IHH, COL2A1, and COL10A1) were significantly
reduced in siLRP1 chondrocytes, confirming that chondrogen-
esis was disrupted after the knockdown of LRP1 expression
(Fig. 6D).
Unlike the knockdown of CRELD2, the knockdown of LRP1 did
not affect matrix mineralization (Fig. 6E) despite a significant
decrease in ALP activity in siLRP1 osteoblasts (Fig. 6F). Many of
the osteoblast markers were also unaffected after the knockdown
of LRP1 (Fig. 6G); however, ALPL, involved in matrix mineralization,
was downregulated and the expressionof the immature osteoblast
Fig. 8. Exogenous WNT4 treatment restores chondrogenic differentiation after the knockdown of CRELD2. (A) Representative images and quantification
of the average area of control (siCON) and CRELD2 knockdown (siCRELD2) mini chondrocyte pellets with and without recombinant WNT4 (rWNT4) treat-
ment. Scale bar = 100 μm. (B) Histology staining of chondrocyte pellets (H&E and immunohistochemistry for collagen II and Aggrecan in red; DAPI nuclear
counterstain in blue). Scale bar = 100 μm. (C) qRT-PCR analysis of CRELD2 and chondrocyte marker genes in siCON and siCRELD2 +/-rWNT4 chondrocytes.
n = 3 per genotype. All graphs are displayed as mean  SD, *p < 0.05, **p < 0.005.
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marker SPP1was upregulated in siLRP1 osteoblasts, indicating that
LRP1 potentially plays a role in early osteoblast differentiation.
WNT4 expression was significantly reduced in siLRP1 chondro-
cytes (Fig. 6D) but was unchanged in siLRP1 osteoblasts (Fig. 6G).
These data suggest that LRP1 drives WNT4 expression during
chondrogenic differentiation, but the expression of WNT4 is
LRP1-independent during osteogenesis.
WNT4 signals via p38 mitogen-activated protein kinase
(MAPK) in chondrocytes and osteoblasts
As previously shown in primary chondrocytes and during hMSC
differentiation, the knockdown of CRELD2 in the chondrocyte-
like SW1353 cell line resulted in a significant reduction of WNT4
expression (Fig. 7A). As observed in siLRP1 chondrocytes, WNT4
Fig. 9. Exogenous WNT4 treatment restores osteogenic differentiation after the knockdown of CRELD2. (A) Alizarin red staining of matrix monolayer of
MSC-derived osteoblasts and quantification of staining intensity. (B) Quantification of ALP activity in siCON and siCRELD2 +/-rWNT4 osteoblasts. (C) qRT-
PCR analysis of CRELD2 and osteoblast marker genes in siCON and siCRELD2 +/-rWNT4 osteoblasts. n = 3 per genotype. All graphs are displayed as
mean  SD, *p < 0.05, **p < 0.005.
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expression was also reduced in siLRP1 SW1353 cells, providing
further evidence that LRP1 drives WNT4 expression in chondro-
cytes (Fig. 7A).
Previous studies have shown that p38 MAPK regulates nonca-
nonical WNT signaling.(35,36) Pharmacological inhibition of p38
signaling inhibits chondrogenesis, suggesting an obligatory role
for p38 MAPK signaling in chondrocyte differentiation.(37,38) To
further dissect the role of noncanonical WNT4 signaling during
chondrogenesis, the p38 MAPK signaling cascade was analyzed
in SW1353 cells by Western blotting. The knockdown of CRELD2
in SW1353 cells did not affect canonical WNT signaling as
β-catenin levels were unchanged; however, it significantly
impaired p38 MAPK signaling as shown by a significant reduc-
tion in the pp38/p38 ratio in CRELD2 knockdown cells (Fig. 7B).
Moreover, the addition of recombinant WNT4 to knockdown
cells restored p38 signaling 15 to 30 minutes post-treatment
(Fig. 7C). Recent studies have shown that LRP1 modulates
WNT5A expression in mouse embryonic fibroblasts by binding
TGF-β1.(39) The expression ofWNT4 in SW1353 cells was upregu-
lated after TGF-β1 treatment, whereas in LRP1 knockdown
SW1353 cells, WNT4 expression was significantly reduced with
and without TGF-β1 treatment (Fig. 7D), indicating that LRP1
modulates WNT4 expression via TGF-β1 in chondrocytes.
As previously observed in primary osteoblasts and hMSCs, the
knockdown of CRELD2 in the osteoblast-like SAOS2 cell line also
resulted in reduced expression of WNT4 (Fig. 7E). The levels of
WNT4 expression were significantly higher in siLRP1 SAOS2 cells
(Fig. 7E), opposite to that observed in siLRP1 SW1353 cells. These
data highlight that WNT4 expression is regulated differently in
chondrocytes and osteoblasts and that WNT4 downregulation
in siCRELD2 osteoblasts is likely to be independent of LRP1. Stud-
ies have shown that noncanonical p38 MAPK signaling is crucial
for osteogenesis as p38 inhibitors blocked osteogenic differenti-
ation.(40,41) Western blotting was therefore used to analyze p38
MAPK signaling in siCRELD2 SASO2 cells. As demonstrated in
the SW1353 cells, canonical WNT/β-catenin signaling in SAOS2
cells was unaffected after the knockdown of CRELD2; however,
p38 MAPK signaling was impaired since there was a significant
reduction in the pp38/p38 ratio in knockdown cells (Fig. 7F). As
already demonstrated in SW1353 cells, this reduction in p38 sig-
naling was restored by the addition of recombinant WNT4 to
siCRELD2 SAOS2 cells (Fig. 7G). Thus, CRELD2 is important for
WNT4 signaling via noncanonical p38 MAPK that has previously
been shown to promote chondrogenic and osteogenic
differentiation.
Exogenous WNT4 rescues the impaired chondrogenic and
osteogenic differentiation of knockdown CRELD2 hMSCs
BecauseWNT4 promotes chondrocyte(3) and osteoblast differen-
tiation(4) we next wished to determine the effects of exogenous
WNT4 on in vitro chondrogenic and osteogenic differentiation of
CRELD2 knockdown hMSCs.
Consistent with experiments shown in Fig. 4, chondrogenesis
was disrupted after CRELD2 knockdown because siCRELD2 pel-
lets were significantly smaller (Fig. 8A, B) and had a disrupted
ECM composition with reduced staining for type II collagen
and aggrecan (Fig. 8B). The addition of exogenousWNT4 rescued
this abnormal cell phenotype; indeed siCRELD2 pellets treated
with WNT4 were significantly larger than the siCRELD2 pellets
and were an equivalent size to control pellets (Fig. 8A). The
expression of ECM structural proteins was restored in siCRELD2
pellets treated with WNT4 (Fig. 8B) and in addition the
expression levels of several chondrogenic markers, which were
significantly reduced in siCRELD2 chondrocytes, were signifi-
cantly increased after the addition of WNT4 (Fig. 8C).
We have demonstrated that the in vitro osteogenic differenti-
ation of hMSCs was delayed after CRELD2 knockdown (Fig. 4E-G).
For example, matrix mineralization and ALP activity were signifi-
cantly reduced in siCRELD2 osteoblasts and this was also rescued
by the addition of exogenous WNT4 (Fig. 9A, B). Moreover, the
knockdown of CRELD2 resulted in downregulation of several
osteoblast marker genes; however, their expression returned to
control levels in siCRELD2 osteoblasts treated withWNT4 (except
for the osteocyte marker gene SOST) (Fig. 9C).
These data indicate that the addition of WNT4 restores the
chondrogenic and osteogenic differentiation of CRELD2 knock-
down hMSCs and confirms that CRELD2 plays an important role
in chondrocyte differentiation and osteoblast maturation by
directly modulating WNT4 signaling.
Discussion
CRELD2 has been identified as an ER-stress-inducible gene
expressed in several tissues(16,17); however, very little is known
about its role in skeletal development and homeostasis. Here
we describe the first in-depth study of Creld2 transgenic mice
and identify a novel important role for CRELD2 in regulating
chondrogenic and osteogenic differentiation.
Creld2CartΔEx3–5 mice displayed a chondrodysplasia-like phe-
notype with abnormal cartilage growth plates, whereas
Creld2BoneΔEx3–5 mice had an osteopenic phenotype with low
bone density and altered trabecular architecture. Transcriptomic
analysis of the knockout tissues showed dysregulation of genes
important for chondrocyte differentiation and proliferation and
for osteoblast maturation. Moreover, in vitro chondrogenesis
and osteogenesis of hMSCs was impaired after CRELD2 knock-
down, indicating that deletion of Creld2 impairs chondrocyte
and osteoblast differentiation and maturation.
WNT signaling plays a major role in controlling skeletal devel-
opment and homeostasis, and, importantly, noncanonical p38
MAPK WNT signaling promotes skeletal cell differentia-
tion(37,38,40,41) Interestingly,Wnt4, encoding a secreted noncano-
nical (β-catenin independent) WNT signaling protein that
modulates chondrocyte maturation(34) and promotes osteo-
genic differentiation,(35) was downregulated in both cell types
after the knockout of Creld2. We confirmed that knocking down
CRELD2 expression reduces noncanonical p38 signaling in both
chondrocyte-like (SW1353) and osteoblast-like (SAOS2) cells,
and importantly, this reduction is restored upon the addition of
exogenous WNT4. Furthermore, we showed that the addition
of recombinant WNT4 was able to rescue the delayed chondro-
genic and osteogenic differentiation of siCRELD2 hMSCs.
To understand how CRELD2 regulatesWNT4 expression, puta-
tive CRELD2 binding partners were identified by co-immunopre-
cipitation. CRELD2 contains an imperfect KDEL ER-retention
sequence (REDL(11)) that is believed to play a role in ER retrieval
and is implicated in toxin endocytosis.(42) We therefore postulate
that the REDL motif functions to retrieve extracellular CRELD2
back into the ER. A search of the UniProt database for proteins
identified only four other mammalian proteins with an REDL
motif. Two of these proteins, Canopy 4 (CPNY4) and Mesoderm
development candidate 2 (MESDC2), function as chaperones
and enhance the folding, maturation, and cell surface expression
of receptors such as toll-like receptors(43) and low-density
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lipoprotein receptors (LRP)(44–46) respectively. Additionally, stud-
ies have shown that an isoform of CRELD1, an ortholog of
CRELD2, enhances the maturation and cell surface expression
of acetylcholine receptors.(47) It is particularly noteworthy there-
fore that we have shown CRELD2 co-immunoprecipitates with
LRP1, and CRELD2 knockdown cells display less LRP1 on the
plasma membrane. We therefore suggest that CRELD2 functions
as a novel LRP1 chaperone by promoting the expression of LRP1
on the cell surface.
Previous studies have shown that LRP1 represses hypertro-
phy, and LRP1 knockdown in mature chondrocytes results in an
upregulation of the hypertrophic marker COL10A1.(48) Here we
show for the first time that LRP1 knockdown in hMSCs disrupted
chondrogenesis and a reduction in WNT4 expression, indicating
that WNT4 expression lies downstream of LRP1 during chondro-
genesis. Additionally, we show that LRP1 modulates WNT4
expression in chondrocytes by binding TGFβ-1. The defect
caused by LRP1 knockdown during chondrogenesis was less
severe than that resulting from CRELD2 knockdown as the reduc-
tion in chondrocyte pellet size was not as pronounced in siLRP1
pellets compared with siCRELD2 pellets, suggesting that CRELD2
may modulate chondrogenesis through other pathways. Addi-
tionally, CRELD2 also co-immunoprecipitated with the pro-
chondrogenic proteins CYR61(33) and TGFβ-1(49) suggesting it
may regulate a wide range of signaling processes during chon-
drogenesis. The knockdown of LRP1 did not affect osteogenesis,
which is consistent with previous studies showing that osteo-
blast differentiation was unaffected in Lrp1 knockout mice. How-
ever, the mice displayed an osteoporotic phenotype due to
increased osteoclastogenesis(50) further supporting the conten-
tion that LRP1 limits receptor activation of RANKL and osteoclas-
togenesis.(51) We found reduced membrane expression of LRP1
in siCRELD2 SAOS2 cells and showed that RANKL is upregulated
after Creld2 knockout in osteoblasts. This suggests that CRELD2
chaperoning of LRP1 to the cell membrane acts as a mediator
of the RANKL/OPG signaling axis and therefore of osteoblast–
osteoclast cross-talk. Moreover, WNT4 expression was not
reduced in siLRP1 osteoblasts, suggesting that CRELD2 modu-
lates osteoblast WNT4 expression and maturation via a different
pathway, potentially through directly binding to TGFβ-1 and
stimulating WNT4 expression.(52)
To summarize, our results propose a novel and important role
of CRELD2 in chondrogenesis and osteogenesis, identifying it as
a novelmodulator ofWNT signaling and as an evolutionarily con-
served chaperone of LRP1, promoting its expression at the cell
surface (Supplemental Fig. S5). To date, no human disease caus-
ingmutations has been identified in CRELD2, but due to its role in
skeletogenesis, it is intriguing to speculate that it might be a
potential genetic locus for skeletal diseases such as osteogenesis
imperfecta (brittle bone disease).
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